Departamento de Gastrenterologia, Hospital Santa Maria, CHLN.
Expert Rev Gastroenterol Hepatol. 2013 Aug;7(6):513-5. doi: 10.1586/17474124.2013.814903.
Evaluation of: In general, nonalcoholic fatty liver disease (NAFLD) consists of ectopic fat accumulation in the liver, when the ability to store fat in inert reservoirs is overcome. That occurs either when we have an excess of energy/fat such as in obesity, or when adipose tissue is defective, not being able to store even regular amounts of energy, such as in lipodystrophies (LDs). LD associates with metabolic deregulation: insulin resistance/diabetes mellitus and dyslipidemia. Several small studies have shown a beneficial effect of leptin replacement, an adipocyte-derived hormone, in the metabolic profile of patients with LD. The paper under evaluation studied 50 patients with LD-associated NAFLD treated with leptin, suggesting a beneficial effect in liver histology and in decreasing not only steatosis, but also nonalcoholic steatohepatitis, although with no effect on fibrosis after 2 years of treatment.
一般来说，非酒精性脂肪性肝病 (NAFLD) 是指肝脏内的异位脂肪堆积，当脂肪储存能力超过惰性储库时就会发生这种情况。这种情况要么是由于能量/脂肪过多，如肥胖，要么是脂肪组织有缺陷，即使是正常量的能量也无法储存，如脂肪营养不良 (LDs)。LD 与代谢失调有关：胰岛素抵抗/糖尿病和血脂异常。几项小型研究表明，脂肪细胞衍生的激素瘦素替代在 LD 患者的代谢特征中具有有益作用。正在评估的论文研究了 50 例接受瘦素治疗的 LD 相关 NAFLD 患者，提示瘦素治疗对肝脏组织学有有益作用，不仅可以减少脂肪变性，还可以减少非酒精性脂肪性肝炎，尽管在 2 年的治疗后对纤维化没有影响。
